Welcome to our dedicated page for LENZ THERAPEUTICS SEC filings (Ticker: LENZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The LENZ Therapeutics, Inc. (Nasdaq: LENZ) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a publicly traded pharmaceutical issuer focused on presbyopia treatment. LENZ uses its filings to report material events related to VIZZ (aceclidine ophthalmic solution) 1.44%, financial results, capital raising activities and other significant corporate developments.
For investors analyzing LENZ, periodic reports and current reports on Form 8-K are key sources of information. Recent 8-K filings referenced by the company include announcements of FDA approval of LNZ100 (VIZZ) for the treatment of presbyopia in adults, the availability of VIZZ in the United States, and preliminary financial results and commercial highlights following launch. Another 8-K describes a block sale of common stock under an at-the-market sales agreement, illustrating how LENZ has raised capital to support its operations and commercialization efforts.
LENZ also uses 8-K filings to furnish press releases with quarterly financial results, which detail items such as cash, cash equivalents and marketable securities, selling, general and administrative expenses, research and development expenses and net loss. While these specific figures change over time, the filings show how the company reports its financial condition and the impact of building a sales force and marketing infrastructure for VIZZ.
Safety-related disclosures can also appear in LENZ filings. In one 8-K, the company describes an adverse event report in the FDA’s FAERS database involving a retinal tear in a patient using VIZZ, outlines the patient’s pre-existing retinal risk factors and notes that a causal relationship to VIZZ remains uncertain. Such filings help investors understand how LENZ communicates about product safety as VIZZ use expands in real-world settings.
On Stock Titan, these SEC filings are complemented by AI-powered summaries that highlight the main points of lengthy documents, making it easier to review items such as quarterly earnings releases, product approval announcements, capital markets transactions and safety updates. Users can track new 8-Ks and other forms as they are filed with EDGAR, and quickly identify disclosures most relevant to LENZ’s commercialization of VIZZ and its overall financial profile.
LENZ Therapeutics, Inc. filed a current report to say it has released a press release with certain preliminary, unaudited financial results for the three months ended December 31, 2025, along with recent corporate updates. These figures are still subject to the company’s normal accounting and annual audit procedures and may change once that work is completed.
The press release is provided as Exhibit 99.1 and is furnished, not filed, meaning it is not automatically subject to certain Exchange Act liabilities or incorporated into other securities filings unless specifically referenced.
LENZ Therapeutics’ Chief Commercial Officer, Shawn Olsson, reported new equity awards. On January 2, 2026, Olsson received a stock option covering 84,200 shares of LENZ Therapeutics common stock at an exercise price of $16 per share, expiring on January 1, 2036. The option vests over time, with 25% of the shares vesting on the one-year anniversary of January 2, 2026 and the remaining shares vesting monthly thereafter while Olsson continues as a service provider.
On the same date, Olsson was also granted 14,000 restricted stock units, each representing a right to receive one share of common stock. These RSUs vest with 25% of the award vesting on the one-year anniversary of the January 2, 2026 grant date, and the rest vesting in equal installments every six months, subject to continued service.
LENZ Therapeutics, Inc. reported an equity grant to its Chief Medical Officer, Marc Odrich, effective January 2, 2026. He received a stock option for 84,200 shares of common stock with an exercise price of $16 per share, expiring on January 1, 2036. The option vests 25% one year after the January 2, 2026 vesting commencement date, with the remaining shares vesting monthly over three years, contingent on his continued service under the company’s 2024 Equity Incentive Plan.
Odrich also received 14,000 restricted stock units (RSUs), each representing one share of common stock. For this award, 25% of the RSUs vest one year after the January 2, 2026 grant date, with the remaining RSUs vesting in eight equal installments every six months, also subject to continued service. Both the options and RSUs are reported as directly owned following these grants.
LENZ Therapeutics Chief Financial Officer Daniel R. Chevallard received new equity awards. On January 2, 2026, he was granted a stock option for 84,200 shares of LENZ Therapeutics, Inc. common stock at an exercise price of $16 per share, with no cash paid for the option itself.
The filing also reports a grant of 14,000 restricted stock units, each representing one share of common stock. Both the option and RSUs vest over time starting from January 2, 2026, and vesting is conditioned on Mr. Chevallard continuing to serve as a Service Provider under the company’s 2024 Equity Incentive Plan.
LENZ Therapeutics described a recently reported retinal tear in a patient using VIZZ (aceclidine ophthalmic solution) 1.44% that was submitted to the FDA’s FAERS database. The company notes that FAERS data alone do not prove a causal relationship, but it reviewed the case under its pharmacovigilance procedures.
The patient had extensive prior retinal problems, including bilateral lattice degeneration, past peripheral laser treatment, and a previous retinal tear, and had not recently undergone a peripheral retinal exam before starting VIZZ. Several days after beginning therapy, on a non-dosing day, the patient noticed vision changes, was diagnosed with a retinal tear, treated with laser retinopexy, and is recovering well. Independent retina specialists highlighted multiple pre-existing risk factors, so any link to VIZZ remains uncertain. Retinal tears naturally occur at about 25 per 100,000 people per year, and this initial report does not change the company’s current safety expectations for VIZZ.
LENZ Therapeutics, Inc. (LENZ) reported a Form 4 for its Chief Commercial Officer, who executed an option exercise and related stock sales on 11/17/2025. The officer exercised a stock option to acquire 10,000 shares of common stock at $2.08 per share, then sold 4,212 shares at a weighted average price of $25.7385 and 5,788 shares at a weighted average price of $26.3669. After these transactions, the officer directly held 4,733 shares of common stock and 53,241 stock options. The sales were made under a Rule 10b5-1 trading plan entered into on August 12, 2025, which is a pre-arranged plan intended to structure trading in advance.
LENZ Therapeutics disclosed an insider purchase. A Director bought 10,500 shares of common stock on 11/07/2025 at a weighted-average price of $22.7884. After the transaction, the Director beneficially owns 10,500 shares directly and 620,599 shares indirectly through a trust. The indirect holdings include 95,034 shares transferred to the McCollum Living Trust on June 6, 2024.
LENZ Therapeutics (LENZ) reported an insider purchase by its Chief Financial Officer, Daniel R. Chevallard. On 11/07/2025, he bought common stock in two open‑market transactions coded “P”: 20 shares at $22.71 and 2,178 shares at $22.7561. Following these trades, he directly owns 5,386 shares.
LENZ Therapeutics (LENZ) reported Q3 2025 results and highlighted FDA approval of VIZZ. The company recorded $12.5 million in license revenue in the quarter and $17.5 million year-to-date. Operating expenses rose with commercialization activities, led by selling, general and administrative of $27.6 million and research and development of $3.8 million, resulting in a net loss of $16.7 million (basic and diluted loss per share of $0.59).
LENZ ended September 30, 2025 with $202.2 million in cash, cash equivalents, and marketable securities and reported 28,540,519 weighted‑average shares outstanding for the quarter. The company sold 920,500 shares via its at‑the‑market program during the nine months ended September 30, 2025 for $26.1 million in net proceeds, and subsequently sold 2,698,134 shares in October at a weighted‑average price of $45.79. On July 31, 2025, the FDA approved VIZZ (aceclidine ophthalmic solution) 1.44% for presbyopia in adults.
LENZ Therapeutics, Inc. furnished a Form 8-K announcing its financial results for the quarter ended September 30, 2025. The company issued a press release, attached as Exhibit 99.1, and incorporated by reference.
The Item 2.02 disclosure and the press release are furnished and not deemed “filed” for purposes of Section 18 of the Exchange Act. Exhibits include the press release (99.1) and the cover page interactive data file (104).
FAQ
What is the current stock price of LENZ THERAPEUTICS (LENZ)?
What is the market cap of LENZ THERAPEUTICS (LENZ)?
